Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS - a Randomised, Placebo-controlled, Double-blind Trial

Next Previous
Trial Profile

Safety and Preliminary Efficacy of Sequential Multiple Ascending Doses of Solnatide to Treat Pulmonary Permeability Oedema in Patients With Moderate-to-severe ARDS - a Randomised, Placebo-controlled, Double-blind Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 22 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Solnatide (Primary)
  • Indications Adult respiratory distress syndrome; Pulmonary oedema
  • Focus Adverse reactions
  • Sponsors APEPTICO Forschung und Entwicklung

Most Recent Events

  • 14 May 2025 Status changed from recruiting to completed.
  • 09 Feb 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2024.
  • 09 Feb 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Dec 2024.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top